NeuroSense Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRSN research report →
Price Chart
About the company
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS).
- CEO
- Alon Ben-Noon
- IPO
- 2021
- Employees
- 17
- HQ
- Herzliya, TA, IL
Get TickerSpark's AI analysis on NRSN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.43M
- P/E
- -0.19
- Fwd P/E
- 0.10
- PEG
- -0.05
- P/S
- 0.00
- P/B
- -0.83
- EV/EBITDA
- -0.27
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 610.97%
- ROIC
- 415.55%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-11,085,000
- Net Income
- $-11,125,000-9.0%
- EPS
- $-8.80+20.0%
- OCF Growth
- +24.3%
- FCF Growth
- +24.3%
- 52W High
- $24.80
- 52W Low
- $1.10
- 50D MA
- $3.59
- 200D MA
- $11.66
- Beta
- 1.72
- RSI (14)
- 27
- Avg Volume
- 31.52K
No earnings-call transcripts are available for NRSN yet.
- Free Float
- 62.9%
- Shares Outstanding
- 1.90M
- Float Shares
- 1.19M
of shares held by institutions
13 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Pathstone Holdings, LLC | 16.53K | 0 |
| Xtx Topco Ltd | 11.47K | ▲ 11.47K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Ben-Noon Alon | buy | 250,000 |
| Jun 16, 26 | Eisenberg Or | buy | 250,000 |
| Mar 26, 26 | Eisenberg Or | other | 200,000 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Aug 15, 24 | Eisenberg Or | other | 0 |
| Jul 1, 21 | Eisenberg Or | other | 0 |
| Mar 18, 26 | Mandil-Levin Revital | other | 0 |
| Mar 10, 23 | Mandil-Levin Revital | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NRSN coverage
Recent articles, reports, and earnings notes.
No research on NRSN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRSN report →NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
prnewswire.com · Nov 2
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
prnewswire.com · Oct 29
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
prnewswire.com · Oct 19
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
prnewswire.com · Oct 13
NeuroSense Provides Update on Nasdaq Listing Compliance
prnewswire.com · Oct 2
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
prnewswire.com · Sep 28
NeuroSense Provides Business Update and Progress for the First Half of 2026
prnewswire.com · Sep 25
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.